Cardiovascular (CV) risk associated with Systemic Erythematosus Lupus (SLE) yet remains an issue of great interest and current debate. Results from a large number of epidemiological studies clearly indicate SLE as a clinical condition associated with an increased CV risk. Such risk is estimated to be as more than twofold higher than what predicted by traditional CV risk factors (CVRFs) such as age, sex, hypertension, diabetes mellitus, dyslipidemia, smoking, sedentary behavior and obesity [1,2].
